Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2519 results about "Epitope" patented technology

An epitope, also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. For example, the epitope is the specific piece of the antigen to which an antibody binds. The part of an antibody that binds to the epitope is called a paratope. Although epitopes are usually non-self proteins, sequences derived from the host that can be recognized (as in the case of autoimmune diseases) are also epitopes.

Monoclonal antibody for identifying canine distemper virus H protein, detection test strip and application

The invention discloses a monoclonal antibody for identifying canine distemper virus H protein, a detection test strip and application. The monoclonal antibody comprises a monoclonal antibody 5-8H or a monoclonal antibody 9-7B and has high specificity and sensitivity, the two antibodies can recognize different epitopes, and a detection test strip can be prepared through a double-antibody sandwich method. Tests prove that the monoclonal antibody provided by the invention has no obvious cross reaction on canine parvovirus, canine adenovirus, canine coronavirus and canine parainfluenza virus in preparation of a colloidal gold test strip for detecting the canine distemper virus, and has good specificity and higher sensitivity.
Owner:HUAZHONG AGRI UNIV

Development, preparation and application of carbapenemase immunochromatography kit

The invention discloses development, preparation and application of a carbapenemase immunochromatography kit, and belongs to the technical field of biological medicines. According to comparison of amino acid sequences of five common carbapenemase variants of KPC, IMP, NDM, VIM and OXA48 types, the immunogen is prepared from conserved epitope sequences obtained respectively. A mouse is immunized, and a specific antibody pair which is strong in affinity and can be combined with multiple variants is obtained through multi-platform screening. On the basis, the carbapenemase quintuplet detection kit is developed by utilizing an immunochromatography method, has the advantages of high sensitivity, good specificity, capability of covering various drug-resistant variants, capability of detecting multiple targets at one time and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

CysR structural domain specific antibody of PLA2R and application thereof

The invention discloses a specific antibody aiming at a CysR structural domain of PLA2R and application of the specific antibody, and belongs to the technical field of biological engineering. The invention provides a CysR structural domain antibody of PLA2R or an antigen binding fragment of the CysR structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CysR structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG with different anti-PLA2R epitopes.
Owner:NANJING VAZYME MEDICAL TECH CO LTD

T cell receptor for identifying KRAS mutation and coding sequence thereof

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.
Owner:SHANGHAI XINPU BIOTECHNOLOGY CO LTD

Anti-TL1A antibody as well as preparation method and application thereof

The invention discloses an anti-TL1A antibody and a preparation method and application thereof in the technical field of biological medicine. The anti-TL1A antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The antibody provided by the invention has relatively high affinity and better biological activity characterization, and the epitope is different from that of a traditional anti-TL1A antibody.
Owner:CHINA RESOURCES BIOPHARMACEUTICAL CO LTD

High-specificity diagnostic reagent and kit for mycobacterium tuberculosis infection

The invention relates to a high-specificity diagnostic reagent and kit for mycobacterium tuberculosis infection, and relates to the technical field of tuberculosis diagnostic products. The fusion protein contains a first fusion protein and a second fusion protein; the first fusion protein is a protein ESAT-6-CFP-10 encoded by a mycobacterium tuberculosis genome RD1 region, and the second fusion protein is a protein CFP-21-MPT-64 encoded by a mycobacterium tuberculosis genome RD2 region. According to the invention, tuberculosis specific RD2 region antigens CFP21 and MPT64 and RD1 region antigens ESAT-6 and CFP-10 are combined to be applied to diagnosis of mycobacterium tuberculosis infection for the first time, by virtue of the difference degree of RD1 and RD2 in mycobacterium antigen cross reactivity, immunogenicity advantages of the two antigens are concentrated, epitopes of the antigens are increased, human MHC limitation and polymorphism are overcome, and advantage complementation is achieved.
Owner:HUAZHONG UNIV OF SCI & TECH

Kit and method for HLA cross reaction group and HPA genotyping

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.
Owner:BEIJING HOSPITAL

CD25 antibodies

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and / or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.
Owner:IBIO INC

Cat allergen fusion protein, mRNA immune preparation and application thereof

The invention relates to the technical field of biological medicine, in particular to cat allergen fusion protein, an mRNA immune preparation and application of the cat allergen fusion protein and the mRNA immune preparation. The amino acid sequence of the cat allergen fusion protein disclosed by the invention is as shown in SEQ ID NO.11. The cat allergen fusion protein provided by the invention is a fusion protein obtained by fusing key segments with strong sensitization of Fel d2 and Fel d4 proteins with Fel d1 full-length protein, the fusion protein can simultaneously cover main sensitization epitopes of Fel d1, Fel d2 and Fel d4, and the sensitization effect of cat allergens can be more comprehensively blocked. According to the cat allergen fusion protein provided by the invention, an mRNA immune preparation can be rapidly designed and synthesized, the expression of the cat allergen fusion protein can be accurately controlled in poultry bodies, the immunoreaction is more durable, and the prepared IgY antibody can effectively block allergic protein in cat oral saliva.
Owner:BEIJING DEAOPING BIOTECHNOLOGY CO LTD

Preparation and application of antibody capable of detecting various IMP variants

The invention discloses preparation and application of an antibody capable of detecting various IMP variants, and belongs to the field of biological medicine. According to the invention, a conserved epitope sequence of IMP enzyme is obtained according to comparison of amino acid sequences of all IMP variants, and an antibody of a spatial epitope is prepared through structural analysis of the epitope. After a mouse is immunized with IMP immunogen protein, hybridoma cells secreting antibodies are obtained through multi-technology platform screening, specific antibody pairs MK35G9 and MK56G2 which are high in affinity and can be combined with multiple IMP variants are obtained after sequencing, and corresponding CDR is obtained through analysis. According to the present invention, the IMP enzyme detection product development is performed based on the immunochromatography platform, such that advantages of high sensitivity, good specificity, covering of a variety of IMP variants, and rapid and convenient detection are provided, and important help is provided for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

Novel recombinant herpes zoster vaccine as well as preparation and application thereof

The invention belongs to the field of biomedicine, and particularly discloses a herpes zoster vaccine as well as a preparation method and application thereof. The invention provides a herpes zoster vaccine. A fusion protein in the herpes zoster vaccine comprises a VZV-gE protein, an Fc and an optional antigen epitope with a cellular immune activation effect. The adjuvant can be a combination of an MF59 adjuvant and a CpG1009 adjuvant, and enhances humoral immunity and cellular immunity at the same time. The vaccine formed by the fusion protein in cooperation with an innovative adjuvant system can induce generation of strong cellular immunity and humoral immunity.
Owner:CHENGDU NANOMICROGEN BIOTECH CO LTD +1

Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use

The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule / binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
Owner:ABSCI CORPORATION

Anti-TL1A antibody as well as preparation method and application thereof

The invention discloses an anti-TL1A antibody and a preparation method and application thereof in the technical field of biological medicine. The heavy chain variable region comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 of which the amino acid sequences are shown as SEQ ID NO: 7-9; the light chain variable region comprises an LCDR1, an LCDR2 and an LCDR3, wherein the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 are shown as SEQ ID NO: 10-12. The anti-TL1A antibody has better biological activity characterization, and the epitope of the anti-TL1A antibody is different from that of the traditional anti-TL1A antibody.
Owner:CHINA RESOURCES BIOPHARMACEUTICAL CO LTD

Monoclonal antibody for specifically detecting rotavirus and application thereof

The invention provides a specific monoclonal antibody for detecting rotavirus and application of the specific monoclonal antibody, aiming at an epidemic strain of porcine rotavirus, reference to a gene sequence of VP6 protein published by GenBank, antigen epitopes are further optimized, and purified recombinant VP6 protein with antigenicity is obtained for animal immunization. The monoclonal antibody capable of specifically recognizing the porcine rotavirus is successfully screened out. The monoclonal antibody obtained through screening can effectively recognize epidemic strains, has broad-spectrum recognition, is superior to commercially available antibodies, and has high antigen recognition target performance and low non-specificity. And the sequence background is clear, large-scale amplification and production can be carried out, and the method has good commercial value.
Owner:NEO-NOSTICS(SUZHOU)BIOENGINEERING CO LTD

Anti-allergen antibodies and uses thereof

The present invention provides antibodies binding to birch pollen allergens, in particular to Bet v 1 allergens, and also binding to Bet v 1 homologous allergens. The present invention also provides compositions and kits comprising distinct antibodies binding to distinct, non-overlapping epitopes of Bet v 1 and Bet v 1 homologous proteins. In addition, the present invention also relates to the use of such antibodies, compositions and kits, e.g. for preventing or treating tree pollen allergies as well as food-related allergies.
Owner:MABYLON AG

Coronavirus vaccine

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
Owner:BIONTECH SE

Anti-human thrombopoietin antibody AF687, kit and application thereof

The invention provides an anti-human thrombopoietin antibody AF687, a kit and application thereof. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can accurately detect the content of human thrombopoietin in serum, is not influenced by heterogeneity of natural protein glycosylation sites, can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia, and has the advantages that compared with an existing detection reagent, the anti-human thrombopoietin antibody is high in sensitivity and high in sensitivity. The false positive rate can be reduced from 13.9% to 2.7%, and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Recombinant fusion protein of respiratory syncytial virus of prefusion conformation and preparation method and application of recombinant fusion protein

The present invention relates to a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a host cell wherein the polynucleotide, the nucleic acid construct or the expression vector is transformed or transfected, a stabilized trimer formed therefrom, and a method for preparing the same. An immunogenic composition comprising any of the foregoing, and its use in the preparation of a vaccine for the prevention and / or treatment of respiratory syncytial virus infection. The RSV-B recombinant F protein comprises at least one specific epitope of the pre-fusion F protein, a stable F protein tripolymer with pre-fusion conformation can be formed, the expression is stable, the form is uniform, and the yield is greatly improved; the formed F protein trimer has good immunogenicity, can stimulate an organism to generate high-level antibody titer, and has great significance in clinical treatment and prevention and control of the respiratory syncytial virus.
Owner:BEIJING BENEWILL TECH DEV CO LTD

Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts. Therefore, a composition of the present disclosure can be very usefully used for combined administration with the trastuzumab antibody for the treatment of cancer, or for the treatment of cancer not treated with trastuzumab.
Owner:GC CELL CORP

Concatemeric peptide epitope RNAs

The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
Owner:MODERNATX INC

Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
Owner:BIONTECH SE

Prediction method for binding affinity of human leukocyte antigen class I molecules and peptide fragments

The invention provides a method for predicting binding affinity of human leukocyte antigen I-type molecules and peptide fragments, and a construction method of the method comprises the following steps: acquiring antigen binding site residues of the human leukocyte antigen I-type molecules, and extracting antigen binding region sequences of the human leukocyte antigen I-type molecules through secondary multi-sequence alignment; respectively generating a human leukocyte antigen class I molecule coding matrix and a peptide fragment coding matrix based on the paired human leukocyte antigen class I molecule-peptide fragment; and then constructing a model of a convolutional neural network to quantify the binding affinity score of the human leukocyte antigen class I molecule and the peptide fragment. The invention develops a method for predicting binding affinity of human leukocyte antigen class I molecules and peptide fragments based on a convolutional neural network by combining physicochemical characteristics of amino acids, complementary epitope sequences of the human leukocyte antigen class I molecules and an interaction relationship among the sequences.
Owner:SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD +2

Monkey pox mRNA immunogen composition capable of rapidly and efficiently enhancing immune response and application of monkey pox mRNA immunogen composition

The invention provides a monkey pox mRNA immunogen composition capable of rapidly and efficiently enhancing immune response and application of the monkey pox mRNA immunogen composition. The composition comprises at least one antigen peptide or structural protein and an immune enhancement factor IL-15. The composition is used for preparing a monkey pox mRNA vaccine capable of efficiently enhancing immune response, and compared with an mRNA vaccine independently coding a corresponding antigen, the composition can induce a high-level neutralizing antibody against monkey pox virus or vaccinia virus with high homology of the monkey pox virus after being inoculated for one time, and can stimulate relatively strong T cell response; 100% immune protection is provided for lethal attack of monkey pox virus and vaccinia virus; when the vaccine is prepared, compared with a mixed single immunogen, a plurality of epitopes of MPXV can be simultaneously coded from one mRNA molecule, and independent expression and non-interference among the immunogens can be realized, so that effective prevention and / or treatment on orthopox viruses such as monkey pox virus and / or vaccinia virus can be realized, and the vaccine has a relatively high clinical application prospect.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN

A combination and application of monoclonal antibodies for specific detection of adenovirus type 5

The present invention belongs to the field of virus detection technology, and specifically relates to a combination and application of monoclonal antibodies for the specific detection of type 5 adenovirus. The antibody combination includes 8B9 and 4A6, which target different epitopes of the HADV‑5 Hexon protein, respectively, and are suitable for a double-antibody sandwich ELISA detection system. Among them, 8B9 is used as a coating antibody, and 4A6 is used as an HRP-labeled detection antibody. The combination of the two can achieve high sensitivity and high specificity detection of HADV‑5 and replication-deficient recombinant type 5 adenovirus, and does not cross-react with other common adenovirus types. The present invention also provides the variable region amino acid sequence and nucleotide sequence of the above-mentioned antibody, as well as an ELISA detection method based on the antibody combination. The method is simple to operate, has good repeatability, and is suitable for the detection of type 5 adenovirus.
Owner:BEIJING SUBENYUANHE BIOTECHNOLOGY CO LTD

Porcine reproductive and respiratory syndrome virus recombinant nanoparticle vaccine as well as preparation method and application thereof

The invention discloses a porcine reproductive and respiratory syndrome virus recombinant nanoparticle vaccine and a preparation method and application thereof, the vaccine contains a recombinant nanoparticle protein, and the protein comprises: (1) a recombinant protein designed based on a PRRSV structural protein epitope; (2) nano-particle protein designed on the basis of ferritin derived from bacteria; and (3) realizing the self-assembly of the recombinant nano particles by virtue of a SpyCatcher-SpyTag system. The vaccine can prevent and control NADC30PRRSV-like strains which are popular in China in recent years, and is used for suppressing propagation of PRRSV variants.
Owner:NANJING AGRICULTURAL UNIVERSITY

Anti-allergen antibodies and uses thereof

The present invention provides antibodies binding to birch pollen allergens, in particular to Bet v 1 allergens, and also binding to Bet v 1 homologous allergens. The present invention also provides compositions and kits comprising distinct antibodies binding to distinct, non-overlapping epitopes of Bet v 1 and Bet v 1 homologous proteins. In addition, the present invention also relates to the use of such antibodies, compositions and kits, e.g. for preventing or treating tree pollen allergies as well as food-related allergies.
Owner:MABYLON AG

T cell receptor-epitope binding specificity prediction method based on multilevel knowledge distillation

The invention discloses a T cell receptor-epitope binding specificity prediction method based on multilevel knowledge distillation, and relates to a T cell receptor-epitope binding specificity prediction method. The method aims to solve the problem that an existing deep learning model is poor in performance when generalized to be free of epitopes. The feature extraction module is constructed by using the convolutional neural network, and the interaction mode between the TCR and the epitope is explored through a bilinear attention mechanism. Thirdly, internal multi-feature knowledge distillation and inter-domain knowledge distillation are carried out, knowledge is extracted from multiple teacher models, and the predictive ability of student models is enhanced; tCR-epitope pairs in a training set are input into the model, and the model is trained; after multiple iterations, a final prediction model is obtained; and inputting the TCR-epitope pair in the test set into the final prediction model to obtain a prediction result, and performing result analysis. The invention belongs to the technical field of biological information.
Owner:HARBIN INST OF TECH

Methods of treatment with anti-PACAP antibodies

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and / or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and / or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
Owner:H LUNDBECK AS

Hybridoma cell strain for recognizing 188th amino acid of highly pathogenic serum type 4 fowl adenovirus Hexon protein, monoclonal antibody and application of hybridoma cell strain

The invention discloses a hybridoma cell strain capable of recognizing 188th amino acid of a highly pathogenic serum type 4 fowl adenovirus Hexon protein, a monoclonal antibody and application of the hybridoma cell strain. The preservation number of the cell strain 2C5 is CGMCC NO.45829, and the monoclonal antibody 2C5 capable of specifically recognizing the highly pathogenic serum type 4 fowl adenovirus hexon Hexon protein is secreted. The amino acid sequence of the antigen epitope recognized by the gene is Hexon protein GPGRNP, wherein the R188 amino acid in the Hexon protein is the key amino acid recognized by the gene. The monoclonal antibody 2C5 prepared by the invention has the specificity of high-pathogenicity FAdV-4, can specifically recognize the high-pathogenicity FAdV-4, has no cross reaction with non-pathogenicity FAdV-4 and FAdV-4 of other serotypes, and can be used as a diagnostic reagent for distinguishing the high-pathogenicity FAdV-4 and the non-pathogenicity FAdV-4.
Owner:YANGZHOU UNIV

Universal HLA antigen presentation prediction method and system based on protein language model and multi-modal neural network

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.
Owner:WUHAN HUADA ZHIYAN TECHNOLOGY CO LTD +1